Background Besides reducing hyperphosphatemia in chronic kidney disease (CKD)
patients, phosphate lowering agents might provide beneficial effects on clinical and …

Background: Hyperphosphatemia is associated with cardiovascular morbidity and mortality
in adults with chronic kidney disease (CKD). Drug therapy has an irreplaceable role in the …

Background. It remains unclear which phosphate binders should be preferred for
hyperphosphatemia management in chronic kidney disease (CKD). Methods. We performed …

Rationale and objective: Data suggest that non-calcium-based binders, and specifically
sevelamer, may lead to lower rates of death when compared with calcium-based binders in …

Patients with progressive chronic kidney disease (CKD) commonly develop mineral and
bone abnormalities and extraskeletal calcifications with following increased cardiovascular …

As kidney disease progresses, phosphorus retention also increases, and phosphate binders
are used to treat hyperphosphatemia. Clinicians prescribe phosphate binders thinking that …

Population-based studies have shown that most patients with advanced chronic kidney
disease (CKD) do not have optimal phosphate levels. Meta-analyses suggest that there is a …

Background: End-stage renal disease (ESRD) is a chronic health care problem associated
with multiple co-morbidities and escalating costs. Disregulation of mineral metabolism …

Introduction: Hyperphosphatemia is a hallmark of advanced chronic kidney disease (CKD)
and associated with adverse outcomes. Preclinical and epidemiological studies strongly …

Hyperphosphatemia and dyslipidemia are common clinically significant conditions in end-
stage renal disease (ESRD). Hyperphosphatemia management is essential; however, use of …